Logotype for Traws Pharma Inc

Traws Pharma (TRAW) investor relations material

Traws Pharma Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Traws Pharma Inc
Q2 2025 earnings summary14 Aug, 2025

Executive summary

  • Advanced clinical programs for COVID-19 and influenza antivirals, with reprioritized plans to maximize near-term value and ongoing discussions for pandemic stockpiling.

  • Phase 2 studies for Ritutrelvir targeting COVID-19, including Paxlovid-ineligible patients, expected to report results by year-end 2025.

  • Deferred initiation of bird flu clinical trial due to low incidence, with regulatory approvals in Australia and South Korea for rapid start if needed.

  • Published strong efficacy data for rigosertib in rare oncology indication, seeking partnership for further development.

  • Management changes included new interim CEO, CFO, and Chairman appointments during Q2 2025.

Financial highlights

  • Q2 2025 revenue was $2.7M, up from $57K in Q2 2024, due to recognition of deferred revenue from a terminated licensing agreement.

  • Net loss for Q2 2025 was $0.9M ($0.11 per share), compared to a net loss of $123.1M ($20.52 per share) in Q2 2024, which included a $117.5M non-cash charge.

  • Cash, cash equivalents, and short-term investments totaled $13.1M as of 06/30/2025, down from $21.3M at 12/31/2024.

  • R&D expenses decreased to $2.3M from $4.0M year-over-year, mainly due to lower oncology and personnel costs.

  • G&A expenses fell to $1.7M from $2.0M, reflecting lower personnel and stock-based compensation.

Outlook and guidance

  • Results from Phase 2 Ritutrelvir studies anticipated by year-end 2025.

  • Focused on advancing Tevoxavir Marboxil for pandemic stockpiling, with trial initiation dependent on bird flu incidence.

  • Committed to partnering legacy oncology assets for further development and commercialization.

  • Expects significant expenses and operating losses to continue; additional financing required for ongoing trials and operations.

  • R&D expenditures in 2025 expected to be higher than 2024 due to virology program investments.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Traws Pharma earnings date

Logotype for Traws Pharma Inc
Q3 202513 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Traws Pharma earnings date

Logotype for Traws Pharma Inc
Q3 202513 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Traws Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for respiratory viral diseases and cancer. The company focuses on creating novel treatments for conditions such as influenza, COVID-19, and various cancers, utilizing advanced drug development technologies including artificial intelligence and machine learning. The company is headquartered in Newtown, Pennsylvania, and its shares are listed on NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage